CC
BMY icon

Centiva Capital’s Bristol-Myers Squibb BMY Stock Holding History

Centiva Capital’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.96M Sell
81,733
-40,450
-33% -$2.36M 0.04% 280
2025
Q4 		$6.59M Buy
+122,183
New +$5.88M 0.05% 217
2025
Q3 		– Sell
-10,859
Closed -$503K – 1153
2025
Q2 		$503K Buy
+10,859
New +$533K 0.01% 951
2025
Q1 		– Sell
-19,671
Closed -$1.11M – 1581
2024
Q4 		$1.11M Buy
19,671
+1,580
+9% +$88.3K 0.02% 503
2024
Q3 		$936K Buy
+18,091
New +$849K 0.02% 891
2024
Q1 		– Sell
-31,945
Closed -$1.63M – 1791
2023
Q4 		$1.64M Buy
31,945
+13,530
+73% +$710K 0.04% 419
2023
Q3 		$1.07M Sell
18,415
-9,023
-33% -$553K 0.02% 600
2023
Q2 		$1.75M Buy
27,438
+20,040
+271% +$1.34M 0.04% 420
2023
Q1 		$513K Sell
7,398
-17,043
-70% -$1.2M 0.01% 826
2022
Q4 		$1.76M Buy
24,441
+16,076
+192% +$1.21M 0.05% 395
2022
Q3 		$594K Sell
8,365
-7,669
-48% -$556K 0.01% 822
2022
Q2 		$1.24M Sell
16,034
-4,076
-20% -$310K 0.03% 517
2022
Q1 		$1.47M Buy
+20,110
New +$1.35M 0.03% 551
2021
Q4 		– Sell
-18,696
Closed -$1.1M – 1215
2021
Q3 		$1.11M Buy
18,696
+13,571
+265% +$894K 0.07% 308
2021
Q2 		$342K Sell
5,125
-2,160
-30% -$141K 0.01% 996
2021
Q1 		$460K Sell
7,285
-9,080
-55% -$565K 0.02% 604
2020
Q4 		$1.01M Buy
+16,365
New +$1.01M 0.04% 269
2020
Q3 		– Sell
-32,013
Closed -$1.88M – 698
2020
Q2 		$1.88M Sell
32,013
-4,492
-12% -$269K 0.11% 109
2020
Q1 		$2.04M Buy
36,505
+2,006
+6% +$123K 0.09% 139
2019
Q4 		$2.21M Buy
34,499
+30,278
+717% +$1.73M 0.11% 185
2019
Q3 		$214K Sell
4,221
-19,941
-83% -$937K 0.01% 496
2019
Q2 		$1.1M Sell
24,162
-26,078
-52% -$1.21M 0.07% 200
2019
Q1 		$2.4M Buy
50,240
+28,490
+131% +$1.42M 0.16% 101
2018
Q4 		$1.13M Buy
21,750
+20,522
+1,671% +$1.1M 0.09% 130
2018
Q3 		$76K Buy
+1,228
New +$72.9K 0.01% 174

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Centiva Capital's BMY Position: Q1 2026 in Review

Centiva Capital reduced its Bristol-Myers Squibb (BMY) stake by 33% in Q1 2026, selling an estimated $2.36M and leaving 81,733 shares worth $4.96M. The position accounts for 0.04% of the portfolio, ranked #280.

Centiva Capital first reported a position in BMY in Q3 2018 and has held it in 25 quarters since. The position peaked at $6.59M in Q4 2025. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Centiva Capital held 81,733 shares of Bristol-Myers Squibb worth $4.96M as of Q1 2026.
  • Centiva Capital sold 40,450 Bristol-Myers Squibb shares in Q1 2026, an estimated $2.36M.
  • Bristol-Myers Squibb made up 0.04% of Centiva Capital's portfolio in Q1 2026, its #280 holding.
  • Centiva Capital first reported a position in Bristol-Myers Squibb in Q3 2018 and has held it in 25 quarters since.
  • Centiva Capital's Bristol-Myers Squibb position peaked at $6.59M in Q4 2025.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Centiva Capital's 13F filing for Q1 2026, filed 14 May 2026.